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Abstract
Objective: To determine the role of markers of plasma protein damage by glycation, oxidation and nitration in
microalbuminuria onset or subsequent decline of glomerular filtration rate (termed ‘‘early GFR decline’’) in patients with
type 1 diabetes.
Methods: From the 1st Joslin Kidney Study, we selected 30 patients with longstanding normoalbuminuria and 55 patients
with new onset microalbuminuria. Patients with microalbuminuria had 8–12 years follow-up during which 33 had stable
GFR and 22 early GFR decline. Mean baseline GFRCYSTATIN C was similar between the three groups. Glycation, oxidation and
nitration markers were measured in protein and ultrafiltrate at baseline by liquid chromatography-tandem mass
spectrometry using the most reliable methods currently available.
Results: Though none were significantly different between patients with microalbuminuria with stable or early GFR decline,
levels of 6 protein damage adduct residues of plasma protein and 4 related free adducts of plasma ultrafiltrate were
significantly different in patients with microalbuminuria compared to normoalbuminuria controls. Three protein damage
adduct residues were decreased and 3 increased in microalbuminuria while 3 free adducts were decreased and one
increased in microalbuminuria. The most profound differences were of N-formylkynurenine (NFK) protein adduct residue
and Nv-carboxymethylarginine (CMA) free adduct in which levels were markedly lower in microalbuminuria (P,0.001 for
both).
Conclusions: Complex processes influence levels of plasma protein damage and related proteolysis product free adducts in
type 1 diabetes and microalbuminuria. The effects observed point to the possibility that patients who have efficient
mechanisms of disposal of damaged proteins might be at an increased risk of developing microalbuminuria but not early
renal function decline. The findings support the concept that the mechanisms responsible for microalbuminuria may differ
from the mechanisms involved in the initiation of early renal function decline.
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Introduction
Diabetic nephropathy is the single most important cause of
renal failure in North America. Patients with type 1 diabetes face a
one in three lifetime risk of developing macroalbuminuria. Despite
the widespread adoption of renoprotective therapies, these patients
remain at high risk for development of end stage renal disease [1].
Identification of risk at the earliest stages of diabetic nephropathy
and identification of the pathological processes that lead to early
loss of glomerular filtration rate (GFR) may permit the
development and implementation of interventions at a stage when
they are most likely to be effective.
The traditional concept of diabetic nephropathy held that
microalbuminuria (as the fundamental early prognostic variable)
heralds macroalbuminuria [2–4], which after long-term exposure
initiates the process of decline in GFR that leads to end stage-renal
disease [5]. However, two key refinements to this concept arose
from systematic longitudinal study. First, contrary to the
traditional model, microalbuminuria proved to be a dynamic
process that was more likely to remit to normal albumin excretion
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(‘normoalbuminuria’) than to progress to macroalbuminuria [6,7].
Second, independent of subsequent progression or remission of
microalbuminuria, approximately one third of patients with new
onset microalbuminuria begin a linear process of early GFR
decline many years before the onset of macroalbuminuria [8,9].
This new concept emphasized the prognostic importance of the
two early markers of diabetic nephropathy: a) the new onset of
microalbuminuria rather than its subsequent trajectory, and b) the
initiation of early GFR decline. These phenotypes may occur
concurrently and subsequently progress at different rates.
Improved understanding of the mechanisms of development of
both microalbuminuria and early GFR decline, identification of
related prognostic biomarkers and therapeutic interventions will
likely lead to improved treatment of diabetic nephropathy [10].
Proteins suffer increased damage by glycation, oxidation and
nitration in diabetes [11–17]. Increased damage to glomerular
proteins was found in experimental diabetes linked to the
development of early-stage diabetic nephropathy [18–21]. Glycation,
oxidation and nitration of plasma protein and related glycation,
oxidation and nitration free adducts – glycated, oxidized and nitrated
amino acids formed by proteolysis of glycated, oxidized and nitrated
proteins, were increased in clinical diabetes [20,22,23]. Therapeutic
agents that induce remission of microalbuminuria in clinical diabetes
– such as angiotensin receptor blockers and high dose thiamine
[24,25]– decreased levels of damage to glomerular and plasma
protein and or levels and flux of related free adducts [18,26]. We
hypothesised that plasma markers of protein damage, glycated,
oxidized and nitrated plasma proteins or related free adducts –
glycated, oxidized and nitrated amino acids formed by the proteolysis
of plasma and other proteins - may be part of the causal pathway for
the development of microalbuminuria and/or early GFR decline.
Proteins in human tissues, plasma and other body fluids suffer
continual spontaneous damage by glycation, oxidation and
nitration in vivo. Important glycation adducts in vivo are the
early-stage glycation adduct, fructosyl-lysine (FL), and advanced
glycation endproducts (AGEs). Important AGEs quantitatively are
hydroimidazolones derived from arginine residues modified by
glyoxal, methylglyoxal and 3-deoxyglucosone, G-H1, MG-H1 and
3DG-H (and related structural isomers), respectively [22]. Other
important and widely-studied AGEs are Ne-carboxymethyl-lysine
(CML), Nv-carboxymethyl-arginine (CMA), Ne-carboxyethyl-ly-
sine (CEL) and pentosidine (PENT). Markers of oxidative damage
to proteins are: methionine sulfoxide (MetSO), dityrosine (DT) and
N-formylkynurenine (NFK) – products of oxidation of tyrosine and
tryptophan residues, respectively. A widely-studied marker of
nitration damage to proteins is 3-nitrotyrosine (3-NT) [27].
In previous reports of the 1st Joslin Study of the Natural History
of Microalbuminuria in Type 1 diabetes we detailed the risk of
early GFR decline [8,9,28,29]. Selecting from this cohort patients
with normoalbuminuria and patients with new onset microalbu-
minuria with or without early GFR decline over 10 or more years
of follow-up, we study the association of plasma protein glycation,
oxidation and nitration with the development of microalbuminuria
and of early GFR decline.
Methods
The protocol and consent procedures were approved by the
Committee on Human Studies of the Joslin Diabetes Center.
Written informed consent was obtained from all participants.
Study Subjects
Among the 943 patients with normoalbuminuria enrolled in the
1st Joslin Study of the Natural History of Microalbuminuria in
Type 1 Diabetes (‘‘The 1st Joslin Kidney Study’’), microalbumin-
uria developed in 109 during the first four years of observation
[6,30]. Eighty-six of the 109 patients (79%) were followed for
greater than 10 years after the onset of microalbuminuria and they
were available for this study. We ranked them according to the
slope of the glomerular filtration rate estimated by serum cystatin
C (GFRCYSTATIN C) over time, expressed as percent change per
year. The protocol used for assessment of early GFR decline has
been described previously [8]. In brief, patients had on average
5.661.9 serum Cystatin C determinations. GFRCYSTATIN C in
ml/min was approximated using the concentration of serum
cystatin C (in mg/L) and application of a formula developed by
MacIsaac et al. for patients with diabetes [31]. The slope of
GFRCYSTATIN C, expressed as percent change per year, was
derived from the linear regression of log-transformed values for
each individual. As previously published, a negative slope or trend
in renal function change greater than 3.2 percent per year
qualified as an abnormal rate of loss (designated ‘early GFR decline’)
[8,32]. We selected 22 subjects with early GFR decline and 33
subjects with stable GFRCYSTATIN C in whom the subsequent
change in renal function did not decline beyond a slope of 23.1
percent per year. The microalbuminuria cases with stable GFR
had a subsequent median slope of 20.95 percent per year
[interquartile range, 21.61 to 20.43] compared to 24.87
[interquartile range, 211.83 to 23.78] in the microalbuminuria
cases with early GFR decline subgroup (p,0.0001).
Selection of Normoalbuminuria Controls. From the 650
patients participating in the 1st Joslin Kidney Study who remained
normoalbuminuric during follow-up we randomly selected 30
individuals who did not have onset of microalbuminuria over the
course of 12 years of follow-up as controls for comparison with the
microalbuminuria cases [33]. These subjects were followed for a
mean of 12.561.9 years from baseline and serum cystatin C for
estimation of GFRCYSTATIN C was obtained an average of 3.661.5
times. The median slope of GFRCYSTATIN C was 20.88 percent
per year [interquartile range, 21.18 to 20.67] (comparison with
microalbuminuria cases, p,0.0001). None of the
normoalbuminuria controls had early GFR decline.
Measurement of protein glycation, oxidation and
nitration adducts. Plasma specimens obtained within the first
4 years of onset of microalbuminuria and within the first 4 years of
follow-up in patients with normoalbuminuria were selected for the
study. Protein glycation, oxidation and nitration adducts were
determined by LC-MS/MS with quantitation by stable isotopic
dilution analysis from stored plasma samples frozen at 285uC
[23]. Eleven analytes were determined: FL, G-H1, MG-H1, 3DG-
H, CML, CMA, CEL, MetSO, NFK, DT and 3-NT by stable
isotopic dilution analysis LC-MS/MS, and PENT by concurrent
fluorescence detection. They were quantified by reference to
calibration curve response of authentic standards. LC-MS/MS
and fluorescence detection was performed with a Waters Acquity
UPLC system with Acquity fluorescence detector and Quattro
Premier XE tandem mass spectrometer. Plasma glycation,
oxidation and nitration free adducts were determined by direct
analysis of plasma ultrafiltrates (12 kDa cut-off). Glycation,
oxidation and nitration adduct residues of plasma protein were
determined after exhaustive enzymatic hydrolysis by consecutive
incubation with pepsin, pronase E, and finally aminopeptidase and
prolidase, under nitrogen [23]. Sample identity was blinded from
the investigator.
Statistical Methods
All statistical analyses were performed in SAS version 9.1 (SAS
Institute, Carey, North Carolina). For the baseline clinical
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variables other than urinary albumin excretion, comparisons
between normoalbuminuria (n = 30) and microalbuminuria
(n = 55) study groups as well as the comparison between
microalbuminuria with stable GFR (n= 33) and the microalbu-
minuria with early GFR decline (n = 22) used means and Student’s
t-tests for continuous variables and percentages and x2 tests for
categorical variables. For urinary albumin excretion and the
plasma free adduct concentrations, two-way comparisons were
made in the log-scale using Wilcoxon rank sum tests and the trend
across the three groups were made by Kruskal-Wallis tests.
Longitudinal measures of log-transformed GFRCYSTATIN C levels
were analyzed using a general linear model which allowed for the
derivation of subject-specific slopes (and subsequently percent
changes per year). To account for the multiple comparisons owing
to inclusion of 12 independent hypotheses on the single dataset (12
adducts were included in each of the analyses of adduct residues
and free adducts), we maintained the family-wise error rate by
considering statistical significance for these tests at a-level,0.0042
using the simple Bonferroni correction method of 0.05/12.
Correlation among the adduct residues and among the free
adducts associated with microalbuminuria were analyzed to
determine redundancy of analytes and association with the slope
of GFRCYSTATIN C using Spearman correlation coefficients.
Results
To investigate factors associated with the pathophysiology of the
initiation of renal function loss, the study groups were derived
from a population composed of patients whose onset of
microalbuminuria was documented in the 1st Joslin Study of the
Natural History of Microalbuminuria in Type 1 Diabetes. Selected
participants has follow-up examinations spanning at least 10 to
12 yr after microalbuminuria onset for determination of the rate of
GFR decline (slopes of GFRCYSTATIN C) and also had stored
plasma available for analysis of the markers of protein damage.
Subjects with new onset microalbuminuria were subdivided into
22 case patients with early GFR decline, defined as a decline of
GFRCYSTATIN C slope exceeding 3.2 percent per year, and a
subgroup of 33 control subjects with stable GFR. The baseline
clinical characteristics of these subgroups, compared with the
longstanding normoalbuminuria group are shown in Table 1
according to microalbuminuria and early GFR decline status.
Statistical comparisons were made in two ways: first, between
patients with normoalbuminuria and microalbuminuria; and
secondly between microalbuminuria patients with subsequent
stable GFR or with early decline in GFR. Patients with
microalbuminuria had a lower age, a higher proportion of
smokers, a higher A1c during the baseline interval, and, by
definition, higher urinary albumin excretion than patients with
normoalbuminuria. They also had GFRCYSTATIN C similar to the
normoalbuminuria controls. Patients with microalbuminuria with
early decline in GFR had higher A1c, total cholesterol and
triglycerides compared to patients with microalbuminuria and
stable GFR. These two groups did not differ in age, proportion of
smokers, or levels of urinary albumin excretion at baseline.
Furthermore, the levels of serum cystatin C or GFRCYSTATIN C
were similar at baseline in microalbuminuria cases regardless of
subsequent stable GFR or early GFR decline.
Table 1. Baseline Clinical Characteristics of the 85 Type 1 Diabetes Subjects classified by presence or absence of Microalbuminuria
and Early Decline in GFR.
Baseline Characteristic
Normo-albuminuria
Group (N=30)
Microalbuminuria
Group (N=55)
P for Group
Comparison
NA vs. MA
P for Subgroup
Comparison* Stable
vs. Early GFR Decline P for trend
Stable GFR
Subgroup (n =33)
Early GFR Decline
Subgroup (n =22)
Male sex (%) 12 (40%) 17 (52%) 9 (41%) 0.52 0.44 0.60 (x2)
Age (years) 41.966.2 36.368.8 37.868.0 0.005 0.51 0.03
Duration of Diabetes (years) 26.368.3 23.068.2 23.668.3 0.10 0.80 0.30
Current Smoking (%) 1 (3%) 13 (39%) 11 (50%) ,0.001 0.44 0.0004(x2)
Systolic Blood Pressure (mmHg) 118.4611.0 121.6614.9 128.3620.1 0.18 0.19 0.08
Diastolic Blood Pressure (mmHg) 73.466.2 76.0610.5 76.668.7 0.25 0.82 0.36
Glycated Hemoglobin A1C
(percent){
7.8161.25 8.7361.10 9.9261.48 ,0.001 ,.001 ,0.0001
Total Cholesterol (mg/dL){ 190634 187640 223639 0.22 0.002 0.004
Triglycerides (mg/dL){ 107697 97656 1576117 0.71 0.02 0.05
Urinary Albumin Excretion
Rate (mg/min){
2-year Baseline Interval{ 11.9 [9.7, 12.3] 45.1 [32.4, 58.2] 47.1 [32.8, 55.1] ,0.001 0.72 ,0.0001
At Time of Adduct
Measurement
6.4 [3.4, 13.6] 74.3 [35.2, 66.8] 59.8 [36.5, 85.5] ,0.001 0.19 ,0.001
Serum Cystatin C (mg/L) 0.7260.08 0.7760.13 0.8560.27 0.04 0.11 0.15
GRFCYSTATIN C (m/min/1.73 m
2) 117.1613.6 111.9618.3 104.6625.8 0.07 0.22 0.15
Values are means 6 standard deviation or median [interquartile range].
P-values for two-way comparisons were obtianed by Wilcoxon rank sum tests, and p-values for the trend across the three groups were made by Kruskal-Wallis tests.
*Comparison made among the two microalbuminuria subgroups.
{These values represent the mean values for all measurements taken during the two-year baseline interval used for classification of new onset microalbuminuria. To
convert values for total cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129.
doi:10.1371/journal.pone.0035655.t001
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Median levels of A1c in the three study groups of samples in
which protein damage markers were measured are given in
Table 2. A1c levels were similar to those in the mean baseline
interval levels shown in Table 1. A1c was higher in patients with
microalbuminuria compared to normoalbuminuria controls
(P,0.001) and A1c was higher in patients with microalbuminuria
and early decline in GFR compared to patients with microalbu-
minuria and stable GFR (P=0.002).
Glycation, oxidation and nitration adduct residues of
plasma protein and related plasma free adducts
Plasma protein contents of FL, NFK and 3-NT adduct residues
were lower in patients with microalbuminuria compared to
normoalbuminuria controls. In contrast to this, plasma protein
contents of G-H1, CEL and PENT residues were higher in
patients with microalbuminuria compared to controls. There was
no significant difference in the plasma protein content of glycation,
oxidation and nitration adduct residues between patients with
microalbuminuria with and without early GFR decline, as shown
in Table 2 and Figure 1, Panel A.
For related free adducts, the plasma concentrations of 3DG-H,
CMA and PENT free adducts were lower in patients with
microalbuminuria compared to normoalbuminuria controls,
whereas the plasma concentration of G-H1 free adduct was
higher in patients with microalbuminuria compared to controls.
There was no significant difference in the plasma concentrations of
glycation, oxidation and nitration adducts residues between
patients with microalbuminuria with and without early GFR
decline, as shown in Table 3 and Figure 1, Panel B.
Among the 6 adduct residues with differences between
microalbuminuria cases and normoalbuminuria controls, we
sought to determine if there was systematic redundancy of their
associations with A1c, with each other, and with the slope of
GFRCYSTATIN C by way of a correlation matrix. Those adduct
residues that shared a Spearman correlation coefficient whose
magnitude exceeded 0.5 were highlighted in bold font.We found
that none of the adduct residues shared substantial correlation
Table 2. Median (and interquartile range) of Plasma Protein Content of Glycation, Oxidation and Nitration Adduct Residues.
NA (n=30) MA (n=55)
P for Group
ComparisonNA
vs. MA*
P for Subgroup
Comparison
Stable vs. Early
GFR Decline* P for Trend*
ADDUCT RESIDUES Stable GFR (n =33) Early GFR Decline (n=22)
Glycated Hemoglobin
A1c{
7.7[6.9, 8.3] 8.5 [7.7, 9.7] 10.1 [8.8, 11.2] ,0.001 0.002 ,0.0001
Monolysyl AGEs{
FL (mmol/mol lys) 6.05 [5.24, 7.70] 4.78 [3.38, 6.11] 5.03 [4.31, 6.69] 0.004 0.19 0.01
CML (mmol/mol lys) 0.107 [0.0951,
0.142]
0.0884 [0.0723, 0.106] 0.0801[0.0664, 0.0957] 0.016 0.30 0.001
CEL (mmol/mol lys) 0.0117 [0.0084,
0.0189]
0.0445 [0.0121, 0.126] 0.042[0.0253, 0.195] ,0.001 0.55 0.001
Fluorescent AGEs{
PENT (mmol/mol lys) 0.000572 [0.000447,
0.000667]
0.000818 [0.00057, 0.00257] 0.000691[0.000523, 0.000916] 0.001 0.29 0.01
Hydro-Imidazolone AGEs{
G-H1 (mmol/mol arg) 0.0797 [0.0566,
0.111]
0.315[0.197, 0.477] 0.351[0.238, 0.393] ,0.001 0.81 ,0.0001
MG-H1 (mmol/mol arg) 0.32 [0.27, 0.48] 0.49 [0.39, 0.61] 0.45 [0.39, 0.48] 0.057 0.04 0.002
3DG-H (mmol/mol arg) 0.24 [0.19, 0.28] 0.31 [0.22, 0.38] 0.33 [0.10, 0.37] 0.37 0.27 0.37
CMA (mmol/mol arg) 0.38 [0.33, 0.53] 0.33 [0.26, 0.45] 0.32 [0.26, 0.40] 0.011 0.49 0.03
Oxidation Adducts
MetSO (mmol/mol met) 43.5 [39.5, 50.6] 45.1 [30.7, 63.4] 31.8 [27.4, 108] 0.60 0.62 0.35
NFK (mmol/mol trp) 0.688 [0.572, 0.809] 0.0921 [0.0604, 0.123] 0.0819 [0.0675, 0.113] ,0.001 0.40 ,0.0001
DT (mmol/mol tyr) 0.0131 [0.00807,
0.0184]
0.0104 [0.00541, 0.0216] 0.00783 [0.00596, 0.0178] 0.44 0.83 0.29
Nitration Adduct
3-NT (mmol/mol tyr) 0.00879 [0.00592,
0.0128]
0.00431[0.00322, 0.00718] 0.00337 [0.00254, 0.00423] ,0.001 0.14 ,0.0001
*P-values for two-way comparisons were obtianed by Wilcoxon rank sum tests, and p-values for the trend across the three groups were made by Kruskal-Wallis tests.
{Values represent the measurement taken in the sample used for measurement of plasma free adducts. These values differ from those presented in Table 1 as the latter
represent the mean values over the two-year baseline interval used for classification of new onset microalbuminuria.
{AGEs: Advanced Glycation endproducts.
NA, Normoalbuminuria. MA, Microalbuminuria. GFR, glomerular filtration rate.
FL, Ne-Fructosyl-lysine. CML, Ne-Carboxymethyl-lysine. CEL, Ne-(1-Carboxyethyl)lysine. PENT, Pentosidine. G-H1, Nd-(5-hydro-4-imidazolon-2-yl) ornithine. MG-H1, Nd-(5-
hydro-5-methyl-4-imidazolon-2-yl)ornithine. 3DG-H, Nd-(5-hydro-5-(2,3,4-trihydroxybutyl)-4-imidazolon-2-yl)ornithine and related structural isomers, .
CMA, Nv-carboxymethylarginine. MetSO, methionine sulfoxide, NFK, N-formylkynurenine. DT, o,o9-dityrosine. 3NT, 3-nitrotyrosine.
doi:10.1371/journal.pone.0035655.t002
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with A1c. However, substantial correlation was observed between
only 4 of the 21 comparisons in the matrix, suggesting minimum
redundancy of each individual marker: 3-NT shared association
with NFK, CEL, and GH1 (spearman correlation coefficients
0.51, 20.52, and 20.54, respectively) while CEL and GH1 shared
a correlation coefficient of 0.70 (Table 4). Similarly, in the
correlation matrix demonstrating the associations between the 4
free adducts with differences between microalbuminuria cases and
normoalbuminuria controls we observed association only between
CMA and GH1 (Table 5). Consistent with the lack of association
of markers of protein damage with cases of early GFR decline as
compared to controls with stable GFR, we also did not observe
substantial association in the rate of GFR loss – represented by the
slope of GFRCYSTATIN C – with protein adducts or adduct
Figure 1. Comparison of Adduct Residue (Panel A) and Free Adduct (Panel B) Concentration in Cases of New Onset
Microalbuminuria compared to Normoalbuminuria Controls. P values indicate the differences between Microalbuminuria Cases versus
Normoalbuminuria Controls for the log-transformed adduct residue concentrations in the Wilcoxon Rank-Sum tests.
doi:10.1371/journal.pone.0035655.g001
Table 3. Median (and interquartile range) of Plasma Concentration of Protein Glycation, Oxidation and Nitration Free Adducts.
NA (n=30) MA (n=55)
P for Group
ComparisonNA vs. MA*
P for Subgroup
Comparison Stable
vs. Early GFR Decline* P for Trend*
FREE ADDUCT
Stable GFR
(n=33)
Early GFR Decline
(n=22)
Monolysyl AGEs{
FL (nM) 282 [180, 416] 262 [170, 332] 252 [183, 439] 0.74 0.14 0.39
CML (nM) 97 [76, 123] 74 [63, 89] 84 [52, 115] 0.02 0.54 0.05
CEL (nM) 40 [ 34, 56] 36 [ 29, 49] 42 [32, 52] 0.07 0.23 0.14
Fluorescent AGEs{
PENT (nM) 1.2 [0.9, 1.5] 0.5 [0.3, 0.9] 0.3 [0.2, 0.9] ,.0001 0.67 ,0.0001
Hydro-Imidazolone AGEs{
G-H1 (nM) 51 [30, 88] 120 [63, 180] 131 [41, 194] ,.0001 0.49 0.0002
MG-H1 (nM) 484 [255, 710] 339 [263, 567] 297 [202, 510] 0.11 0.90 0.29
3DG-H (nM) 75 [59, 89] 55 [52, 62] 58 [38, 84] 0.001 0.66 0.004
CMA (nM) 330 [288, 471] 70 [37, 182] 65 [40, 156] ,.0001 0.86 ,0.0001
Oxidation Adducts
MetSO (nM) 988 [826, 1639] 806 [594, 1294] 850 [502, 1269] 0.01 0.31 0.04
NFK (nM) 27 [21,34] 22 [18,29] 22 [18,25] 0.39 0.60 0.09
DT (nM) 1.7 [1.3, 2.0] 1.4 [0.9, 2.1] 1.8 [1.5, 2.0] 0.85 0.09 0.39
Nitration Adduct
3-NT (nM) 0.7 [0.6, 0.8] 0.8 [0.6, 1.3] 0.9 [0.5, 1.4] 0.02 0.72 0.14
*P-values for two-way comparisons were obtianed by Wilcoxon rank sum tests, and p-values for the trend across the three groups were made by Kruskal-Wallis tests.
{AGEs: Advanced glycation endproducts.
NA, Normoalbuminuria. MA, Microalbuminuria. GFR, glomerular filtration rate.
FL, Ne-Fructosyl-lysine. CML, Ne-Carboxymethyl-lysine. CEL, Ne-(1-Carboxyethyl)lysine. PENT, pentosidine, G-H1, Nd-(5-hydro-4-imidazolon-2-yl) ornithine, MG-H1, Nd-(5-
hydro-5-methyl-4-imidazolon-2-yl)-ornithine, 3DG-H, Nd-(5-hydro-5-(2,3,4-trihydroxybutyl)-4-imidazolon-2-yl)ornithine and related structural isomers.
CMA, Nv-carboxymethylarginine. MetSO, methionine sulfoxide. NFK, N-formylkynurenine. DT, o,o9-dityrosine. 3NT, 3-nitrotyrosine.
doi:10.1371/journal.pone.0035655.t003
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residues, shown in the last rows of Table 4 and Table 5,
respectively.
Discussion
In the analysis of a type 1 diabetes cohort with normoalbumi-
nuria followed longitudinally for the development of microalbu-
minuria and subsequent early GFR decline, we found a striking
association of plasma protein contents of 6 adduct residues and
plasma concentrations of 4 free adducts of protein damage with
the new onset of microalbuminuria. Contrary to the prevailing
assumptions about plasma markers of protein damage, the
majority had lower levels at the new onset of microalbuminuria
as compared to those with longstanding normoalbuminuria
irrespective of subsequent GFR changes. These markers were
generally either not associated or inversely correlated with levels of
A1c, and they did not strongly associate with each another.
The plasma protein content of glycation, oxidation and
nitration adduct residues relates positively to the in situ rate of
glycation, oxidation and nitration of plasma protein and negatively
to the rate of plasma clearance and repair of damaged plasma
proteins. In previous work, it was observed that the levels of
glycation, oxidation and nitration adduct residues of plasma
protein of patients with type 1 diabetes and normoalbuminuria
were higher compared to healthy controls: FL, CEL, G-H1, MG-
H1, 3DG-H, PENT, MetSO, NFK and 3-NT were all 2–4-fold
higher [20]. In the current analysis, however, we evaluated
changes in plasma protein damage markers in patients with type
1diabetes with and without new onset microalbuminuria, and in
microalbuminuria the effect of subsequent early GFR decline. In
previous studies of patients with type 1 diabetes and normoalbu-
minuria, higher plasma protein content of FL correlated strongly
with higher A1c [20]. In our cohort we found that patients with
new onset microalbuminuria had greater glycemic exposure, as
represented by higher levels of A1c, compared to patients with
longstanding normoalbuminuria. It might be expected that FL and
AGE content of plasma protein are higher in patients with new
onset microalbuminuria – related to increased exposure to plasma
glucose concentration and downstream formation of FL and AGEs
[20]. To the contrary, we see a strong pattern of lower levels of
circulating adduct residues for FL, 3-NT and NFK. Decreased
content of FL residues likely reflects increased selective clearance
of FL-modified albumin as the glomerular filter widens. Support-
ing this, an increased FL residue content of albumin excreted in
Table 4. Matrix of Correlation Between the Adduct Residues with Significant Differences Between Microalbuminuria Cases and
Normoalbuminuria Controls.
GLYCA1C NFK 3NT FL CEL GH1 PENT
Slope of
GFRCYSTATIN C*
GLYCA1C 1
NFK 20.45, p,0.0001 1
3NT 20.25, p = 0.02 0.51, p,0.0001 1
FL 0.14, p = 0.20 0.11, p 0.32 0.27, p 0.014 1
CEL 0.17, p = 0.12 20.35, p = 0.001 20.52,
p,0.0001
0.05, p = 0.68 1
GH1 0.29, p = 0.008 20.44, p,0.0001 20.54,
p,0.0001
0.01, p = 0.92 0.70,
p,0.0001
1
PENT 0.09, p = 0.42 0.04, p = 0.71 0.28, p = 0.01 20.24, p = 0.03 20.07, p = 0.51 20.03,
p = 0.77
1
Slope of GFR
CYSTATIN C*
20.38, p = 0.0004 0.28, p = 0.01 0.3, p = 0.005 0.06, p = 0.58 20.25, p = 0.02 20.27,
p = 0.01
20.06, p 0.591
The top number in each cell is the Spearman Correlation Coefficient r, while the bottom number is the p-value obtained from testing the hypothesis r= 0. P-values are
not applicable for entries on the diagonal. Spearman Correlation Coefficients with magnitude $0.5 are indicated in bold.
*Slope is reported by percent change per year, as described in Methods.
doi:10.1371/journal.pone.0035655.t004
Table 5. Matrix of Correlation Between the Free Adducts with Significant Differences Between Microalbuminuria Cases and
Normoalbuminuria Controls.
GLYCA1C CMA PENT 3DGH GHI Slope of GFRCYSTATIN C*
GLYCA1C 1
CMA 20.47, p,0.0001 1
PENT 20.2, p = 0.07 0.33, p 0.002 1
3DGH 20.26, p = 0.016 0.25, p = 0.02 0.33, p 0.002 1
GH1 0.11, p = 0.34 20.52, p,0.0001 20.11, p = 0.33 0.24, p = 0.03 1
Slope of GFRCYSTATIN C* 20.38, p = 0.0004 0.29, p = 0.008 0.21, p = 0.05 0.06, p = 0.61 20.15, p 0.18 1
The top number in each cell is the Spearman Correlation Coefficient r, while the bottom number is the p-value obtained from testing the hypothesis r= 0. P-values are
not applicable for entries on the diagonal. Spearman Correlation Coefficients with magnitude $0.5 are indicated in bold.
*Slope is reported by percent change per year, as described in Methods.
doi:10.1371/journal.pone.0035655.t005
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urine of patients with diabetes and microalbuminuria compared to
patients with diabetes and normoalbuminuria has been previously
observed [21]. Such an observation implies that the mechanism
for our observed higher circulating levels of adduct residues may
be an increased clearance of those markers. If indeed microalbu-
minuria is associated with increased clearance of FL-modified
albumin, the use of agents that decrease intra-glomerular pressure
such as angiotensin receptor blockade would be anticipated to
attenuate such clearance. Such increased retention of FL-modified
albumin has been observed in a study that administerd angiotensin
receptor blockade to patients with type 2 diabetes and microal-
buminuria [26]. As the use of renin-angitoensin-aldosterone
system inhibition such as angiotensin receptor blockade was not
observed in this new onset microalbuminuria cohort assembled in
the early 1990’s, the finding of lower levels of the three adduct
residues in the microalbuminuric subjects may be explained by an
increase in their clearances. The lower levels of NFK and 3-NT
adduct residues in plasma protein may additionally be due to
decreased oxidative degradation of FL residues in plasma protein.
The observation of higher plasma protein G-H1, CEL, and
pentosidine residue content in patients with microalbuminuria is
likely explained by increased exposure of plasma protein to the
precursor glycating agents glyoxal, methylglyoxal and pentose-
derived dicarbonyls, respectively. This may arise from decreased
quality of glycemic control - as indicated by positive correlations of
plasma protein G-H1, CEL, and pentosidine residue content with
A1c.
Free adducts of protein glycation, oxidation and nitration in
plasma originate from proteolysis of glycated, oxidized and
nitrated proteins in tissues, plasma and other body fluids. The
levels of plasma glycation, oxidaton and nitration free adducts
relate positively to whole body flux of glycation, oxidation and
nitration of proteins and rates of tissue proteolysis, and negatively
to glycation, oxidation and nitration adduct repair and renal
clearance. The levels of plasma glycation and oxidation free
adducts of patients with type 1 diabetes and normoalbuminuria
were increased compared to healthy controls. Specifically, free
adducts of FL, CML, CEL, G-H1, MG-H1, 3DG-H and MetSO
were all increased from 2–10-fold [20]. As with the plasma protein
adduct residue described above, we also assessed differences in the
free adduct plasma protein damage markers in patients with type
1diabetes with and without new onset microalbuminuria. The
increased G-H1 free adduct in new onset microalbuminuria may
relate to increased flux of formation of G-H1-modified protein,
feeding through to increased plasma G-H1 concentration by
proteolysis. Decreases in plasma concentrations of 3DG-H,
pentosidine and CMA in new onset microalbuminuria, compared
to normoalbuminuria controls, are unlikely to reflect decreased
flux of formation of these adducts as glucose exposure was higher.
Neither are these changes likely to reflect increased adduct repair -
as no repair processes are known - or to reflect inhibition of tissue
proteolysis as in this case all protein damage free adducts would be
expected to be lower. Rather these decreases may reflect increased
renal clearance of 3DG-H, PENT and CMA free adducts,
probably mediated by impaired tubular reuptake since these
adducts pass readily through the glomerular filter (molecular mass
,500 Da). Renal clearances of AGE free adducts increase in type
1 diabetes with normoalbuminuria, compared to healthy controls,
and may increase further in new onset microalbuminuria [20].
There was no correlation of any of the protein damage adduct
residues of plasma protein nor concentrations of related free
adduct with subsequent early GFR decline. This suggests that
glycation, oxidation and nitration of plasma proteins may not be
strongly linked mechanistically to early GFR decline. The same
may apply for plasma concentrations of protein glycation,
oxidation and nitration related free adducts – although the many
influential factors affecting levels of these analytes - whole body
flux of glycation, oxidation and nitration of proteins, rates of tissue
proteolysis, glycation, oxidation and nitration adduct repair and
free adduct renal clearance – may make a link difficult to discern.
The strengths of this study are: (a) analysis of an inception
cohort of observed new onset microalbuminuria cases, (b) use of
the best available methods for evaluation of markers of protein
glycation, nitration and oxidation and analysis of a comprehensive
range of protein damage adducts, and (c) discrimination between
protein glycation, oxidation and nitration adducts in plasma
protein and related free adducts – the former resistant to filtration
and the latter readily filtered by the renal glomeruli [34].
However, the current study has potential limitations. Firstly,
glycation, oxidation and nitration adduct residues of plasma
protein may be formed and repaired beyond the systemic
circulation – such as during the renal retrieval pathway for
albumin [35]. This is, however, considered to have a minor
influence except on repair of MetSO [36]. Similarly, glycation,
oxidation and nitration free adducts are partly sourced from
absorption from the gastrointestinal tract following digestion of
ingested glycated, oxidized and nitrated proteins [37,38]. This is
usually a minor source for the free adducts studied herein as
decrease in food consumption had a minor effect on glycation,
oxidation and nitration free adduct concentration in diabetes [17].
Moreover, the finding of a subset of free adducts with lower
plasma concentration implies that dietary exposure is an unlikely
mechanism of early renal injury [39]. Secondly, the study has
limited statistical power to resolve complex associations of multiple
mechanisms of protein damage, development of microalbuminuria
and early GFR decline. Thirdly, we have not studied similar effects
in patients with type 2 diabetes which will be an important focus
for future studies. It is interesting to note that a recent cross-
sectional study of retinopathy in patients with type 1 diabetes of
longstanding duration found a link between the presence of
retinopathy and a combination of higher total plasma CEL and
PENT adducts, but lower CML and FL [40].
We conclude that complex processes appear to influence levels
of markers of plasma protein damage and plasma levels of related
proteolysis product, free adducts, in patients with type 1 diabetes
and microalbuminuria with and without early GFR decline. The
effects observed likely relate to change in glomerular filter
permeability of damaged proteins and change in tubular re-
uptake of free adducts in microalbuminuria. Further research is
required to evaluate involvement of these likely mechanisms of
renal dysfunction.
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